English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
SHALBY INVESTOR RELATIONS
Shalby Limited (NSE: SHALBY) and Stock Exchange Information (BSE: 540797) is India’s leading multi-specialty hospital operating a chain of 11 tertiary hospitals with an aggregate bed capacity of over 2,000 hospital beds. It is one of the top hospitals in joint replacement surgery in India. Shalby is the number one player worldwide for knee replacement surgery and has a 4,000 plus in-house team of skilled doctors, surgeons and support staff. The objective of the Investor Relation Website is to ensure continuous and open communication with its shareholders and all financial market participants.
| Registered Office | |
|---|---|
| Name | Shalby Limited |
| Address | Opp. Karnawati Club,Sarkhej Gandhinagar Highway,Near Prahlad Nagar Garden,Ahmedabad – 380 015, Gujarat, India |
| Phone | +91 79 4020 3000 |
| Fax | +91 79 4020 3120 |
| CIN | L85110GJ2004PLC044667 |
| Grievance Redressal & Nodal Officer | |
|---|---|
| Name | Mr. Tushar Shah (Associate Vice President and Company Secretary) |
| Companysecretary@shalby.in | |
| Phone | +91 79 4020 3000 / +91 79 40203296 |
| Investor Relations | |
|---|---|
| Name | Mr. Puneet Maheshwari |
| ircs3.corp@shalby.org | |
| Phone | +91 9512049071 |
| Registrar & Transfer Agent | |
|---|---|
| Name | KFIN Technologies Limited |
| Address | Selenium Building, Tower-B, Plot No 31 & 32,Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana India - 500 032. |
| einward.ris@kfintech.com | |
| Phone | 1800 309 4001 |
| +91 910 009 4099 | |
| KPRISM | |
| KFIN Corporate Website Link | |
| Corporate Registry (RIS) Website Link | |
| Investor Support Centre Link | |
Investors
For Investors holding shares in Physical mode
If you have any dispute against a listed company and or its Registrar and Share Transfer Agent (RTA) on delay or default in processing your request, as per SEBI circular dated 30.05.2022 , you can file for arbitration with Stock Exchange.
For more details, please see the web links of the stock exchanges BSE - http://tiny.cc/m1l2vz NSE - http://tiny.cc/s1l2vz
Q4 FY 2023 Press Release
Q3 FY 2023 Press Release
Q2 FY 2023 Press Release
Q1 FY2023 Results Press Release.
Launch of TUKS – A New Innovative Knee Implant
Q4 FY2022 Results Press Release
Q3 FY2022 Results Press Release
Q2 FY2022 Results Press Release
Q1 FY2022 Results Press Release
Acquired Implant Assets From Consensus Orthopedics(May 2021)
Shalby Limited Q2 FY2021
Shalby Limited Q3 FY2021
Q2 FY2020 Financial Results
India Facing Knee Arthritis Epidemic (Nov 2018)
Ovarian Mass Removal Jaipur (Sep 2018)
MoU with Sen Sok Intl Hospital, Cambodia (Apr 2018)
Disclosure under SEBI PIT Reg. 7(2) Announcement - Dr. Purvish Parikh as -Group Advisor Press Release - Radiation Therapy Centre, Jaipur Press Release - Radiation Therapy Centre, Naroda, Ahmedabad Authorization to KMP under Reg. 30 of SEBI LODR Statement of Investors Complaints – Q3 FY 2017-18 Disclosure under SEBI PIT Reg. 7(2) Intimation about Loss of Share certificates Press Release – MoU with with Gleneagles Global Health City for Heart & Lung Transplants Program
Statement of Investor Complaints – Q4 FY 2017-18 Share Capital Audit – 31-03-2018 Compliance Certificate under Reg. 7(3) of LODR Press Release – MoU with Sen Sok Intl Hospital, Cambodia Certificate under Regulation 40(10) of SEBI LODR Joint Replacement Surgeries under Mukhyamantri Amrutam Yojana Change in CIN Schedule of Investor / Analyst Meet Schedule of Investor / Analyst Meet – 27-04-2018 Intimation Conference Call Intimation Appointment of CDSL as designated depository Collaboration with Berkeley Health Education Investor/Analyst meeting with Motilal Oswal Securities Limited Investors meet/UBS India- Midcap conference Resignation of Chief Executive Officer of the Company Intimation Analyst meet HDFC Securities 26-06-2018 Updates relating to resignation of CEO Man of the Year Award – Dr. Vikram Shah Intimation Analyst meet – 26-06-2018 Intimation Analyst meet - 27-06-2018 Intimation Analyst meet - 02-07-2018 Intimation Analyst meet – 06-07-2018 Intimation Liver Disease and Transplantation Karvy Reconciliation Report Investor Grievance report Intimation of AGM Intimation of Book closure AGM Notice & Annual Report 2017-18 Newspaper Ad. AGM, Book closure & E-voting Outcome of AGM Voting Results Shalby Press Release - Ovarian Mass Removal Jaipur Credit Rating ICRA Reg 30 LODR Reg 30 Orthotrends 2018 Chandigarh Intimation under Regulation 30 of SEBI LODR-concall with Edelweiss Investor Grievance Report Q2 FY 2018-19 Share Capital Audit Q2 FY 2018-19 Compliance Certificate 7(3) – 30-09-2018 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2018-19 Pre Accreditation Entry level NABH at Shalby Surat Intimation for Conference call Submission of newspaper AD – Notice of Board Meeting Pre-Accreditation Entry level NABH at Shalby Naroda Newspaper ad for Issue of Duplicate Shares Intimation Analyst Meet – Nalanda Capital Intimation participation in IDFC Investor Conference Investor conference Kotak Intimation Issue of Duplicate Shares Press Release Kolkata Intimation Transfer of operations Karvy Medical Value Travel Specialist Hospital Award 2018 Best hospital for Medical Tourism in Gujarat Award Share Capital Audit Q3 FY 2018-19 Intimation of Investor Analyst Concall Intimation of Conference Call Intimation Analyst meet - DSP BlackRock Investment Newspaper ad for Q3 FY 2018-19 Results
Intimation of Trading Window Closure Compliance Certificate 7(3)-31-03-2019 Intimation Of Analyst Meet Certificate under Regulation 40(10) of SEBI LODR –H2 FY 2018-19 Reconciliation of Share Capital Q4 2018-19 Interaction with electronic media Recommendation of Dividend for FY 2018-19 Schedule of Investor / Analyst Meet Q4 FY19 Submission of newspaper ad results Q4 FY2018-19 Disclosure under SEBI PIT Reg. 7(2) 30.05.2019 Disclosure under SEBI PIT Reg. 7(2) 01.06.2019 Intimation of Trading Window Closure Best IT enabled Hospital Award Reconciliation of Share Capital Q1 2019-20 Certificate under Regulation 74 (5) Q1 2019-20 Schedule of Investor Conference Call Q1 FY19 News Paper Advertisement PAS-1 AGM Participation in Emkay Confluence at Mumbai – 08-Aug-2019 Participation in Elara Annual Conference at Mumbai-– 05-September-2019 Gujarat HealthCare Leadership Award 2019 Intimation of Trading Window closure – Q2 FY 2019-20 Fin. Results Dare to Dream -Zee Business Award - Company of the Year Credit Rating ICRA Reg 30 LODR Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2019-20 Clarification Of Price Movement Investor Con-call Q2 FY2019-20 Press Release- Q2FY20 Financial Results Submission of newspaper ad results Q2 FY2019-20 Change of name of Registrar & Transfer Agent Intimation of Trading Window closure – Q3 FY 2019-20 Fin. Results Compliance Certificate Q3 30-09-2019 Reconciliation of Share Capital Audit Report Q3 FY 2019-20 Change in Details of RTA Investor Con-call Q3 FY2019-20 Clarification as to increase in volume of shares Re-appointment of CMD Submission of newspaper ad results Q3 FY2019-20 Disclosure under SEBI PIT Reg. 7(2) 26.02.2020
Intimation Of Subsidiary Company Con-call with Investors to address general queries about ongoing COVID-19 pandamic Con-call with Investors hosted by HDFS Sec to address general queries about ongoing COVID-19 pandemic Clarification Of Price MOvement To NSE Clarification Of Price MOvement To BSE Intimation of Testing of COVID-19 cases at Indore Shalby Hospital Con-call intimation hosted by Edelweiss Con-call intimation hosted by Edelweiss Compliance Certificate 7(3) – 31-03-2020 Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018 Treatment of Covid-19 Patient at Shalby Hospital Conference call hosted by Centrum Broking Ltd. Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2019-20 Reconciliation of Share Capital Audit Report Q4 FY 2019-20 Disclosure as to Large Corporate Schedule of Investor / Analyst Meet Q4 FY20 Trading Window Closure Notice For Q1 FY2021 Intimation of Treatment of Covid-19 Patient at Shalby Hospital, Surat Intimation of Treatment of Covid-19 Patient at Shalby Hospital, Vapi Credit Rating ICRA Reg 30 LODR Certificate under Regulation 74 (5) Q1 2020-21 Disclosure of impact of CoVID-19 on the business and operations Reconciliation of Share Capital Audit Report Q1 FY 2020-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome” Announcement under Secretarial Compliance Report FY 2019-20” Aquisition Subsidiaries Investor Call Intimation Submission of newspaper ad for results Q1 FY2020-21 Notice of 16th Annual General Meeting Intimation of Board of Directors Meeting Outcome of Board meeting Compliance Certificate 7(3) – 30-09-2020 Certificate under Regulation 74 (5) Q2 2020-21 Investor Conference Call Q2 F.Y. 2020-21 Newspaper Ad for Results Q2 FY 2020-21 Certificate under Regulation 40(10) of SEBI LODR –H1 FY 2020-21 Reconciliation of Share Capital Audit Report Q2 FY 2020-21 Investor Analyst Call Intimation Of Subsidiary Company SHMPL Intimation Of Subsidiary Company SHMPL Certificate under Regulation 74 (5) Q3 2020-21 Schedule of Investor / Analyst Meet Q3 FY2021 Shalby Limited Q3 FY2021 Press Release Reconciliation of Share Capital Audit Report Q3 FY 2020-21 Investor / Analyst Meet Change in Company Secretary & Compliance Officer Disclosure under Regulation 30 (5) of the SEBl - LODR Annual Secretarial Compliance Report FY2021 Reconciliation of Share Capital Audit Report Q4 FY2021
Concall Invite Q4 FY2022 Annual Secretarial Compliance Report FY2022 Newspaper Advertisement for Q4 FY2022 Results Certificate under Reg. 40(10) of SEBI (LODR) – FY 2022 Disclosure of Large Corporate (Apr 2022) Reconciliation of Share Capital Audit Report Q4 FY 2022 Certificate ur. 74(5) – Q4 FY 2022 Certificate ur. 7(3) - FY 2022 Further Investment by MMDL in SGTPL (Mar 2022) Change in Name of Registrar & Transfer Agent (Mar 2022) Schedule of Investor-Analyst Meet (Mar 2022) Schedule of Group Investor-Analyst Meet (Mar 2022) Inauguration of SOCE in Ahmedabad (Mar 2022) Receipt of Import License to Subsidiary - MMDL (Feb 2022) Schedule of Investor-Analyst Meet Q3 FY2022 Determining Materiality of an Event/Info by KMPs(Feb 2022) Appointment of Chief Financial Officer (Feb 2022) Further Investment by MMDL in SAT (Jan 2022) Certificate Under Reg. 74(5) Q3 FY 2022 Reconciliation of Share Capital Audit Report Q3 FY 2022 Resignation of Chief Financial Officer (Dec 2021) Further investment by MMDL in SGTPL (Dec 2021) Schedule of Investor-Analyst Meet (Nov 2021) Long Term Credit Rating for Enhanced Rated Amount (Nov 2021) Newspaper Advertisement for Q2 FY2022 Results Schedule of Investor-Analyst Meet Q2 FY2022 Reconciliation of Share Capital Audit Report Q2 FY2022 Upgradation of Credit Rating (Sep 2021) Revised Conference Call Invite (Aug 2021) Conference Call Invite (Aug 2021) Mars Medical Acquires 96% Shares in Shalby Global (Jul 2021) Reconciliation of Share Capital Audit Report Q1 FY2022 Certificate Under Reg. 74(5) (Jun 2021) Reg. 30 of SEBl (LODR)- Inaugurated Shalby Zynova (Jun 2021) Conference Call Invite & Investor Presentation (May 2021) Appointment of Vice Chairman & Global President (May 2021) Concall Invite for Audited Financials-Q4 & FY2021 (May 2021) Step-down Subsidiary in USA (May 2021) Newspaper Publication - Offer for Sale (Apr 2021) Disclosure of Large Corporate (Apr 2021)
Concall Invite Q4 FY 2022-23 concall recording Q4 FY2022-23 Concall Invite Q4 FY2023 Outcome of Board Meeting for year ended March 31, 2023 Certificate under 40(10) Reconciliation of Share Capital Audit Report Q4 FY 2022-23 Certificate ur. 74(5) – Q4 FY 2023 Certificate ur. 7(3) - FY 2023 Closure of Trading Window for Q4 FY 2022-23 Allotment of Preference Shares to Shalby Ltd by Mars Medical Devices Limited Further Investment by MMDL in SGTPL (Mar 2023) Signing of MOU with Silver Oak University by Shalby Academy. Schedule of Investor Meet (Feb 2023) Receipt of Import License by Step-down subsidiary – Shalby Global Technologies Pte. Ltd., Singapore Signing of MOU with IIPH Gandhinagar by Shalby Academy Schedule of Investor / Analyst meet Update On Vrundavan Shalby Hospitals Limited - Wholly Owned Subsidiary Inauguration of Shalby Orthopedics Centre of Excellence (SOCE) at Gwalior Reconciliation of Share Capital Audit report Q3 FY 2022-23. 93ScheduleConcall as Concall Invite Q3 FY 2023 94Reg745 as Certificate ur. 74(5) – Q3 FY 2023 Closure of Trading Window for Q3 FY2023 Allotment to Shalby Ltd by Vrundavan Shalby Hospitals Ltd. Reaffirmation of Credit Rating Conversion of Loan of MMDL to SAT into Preferred Stock and Common Stock Schedule of Investor Meet ( Dec 2022) Shalby Issued SBLC Amounting To USD 9.45 Million For Shalby Advanced Technologies, Inc. USA Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 07-12-2022 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 07-12-2022 Further Investment by MMDL in SGTPL (Dec 2022) Demise of Mr. Kiritbhai Chimanlal Shah, Promoter Group Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 29-11-2022 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 29-11-2022 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 – 17-11-2022 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 – 17-11-2022 Grant of ESOPs Newspaper Ad – Postal Ballot 2022 Disclosure under Reg 7(2) of SEBI (PIT) Reg, 2015 Disclosure under Reg 29(2) of SEBI (SAST) Reg, 2011 Appointment of Mr. Parag Agarawal as Chief Business Officer Calendar of Events for Postal Ballot Process. Newspaper Advertisement for Q2 FY2023 Results Initial Disclosure under SEBI(PIT) Reg, by Mr. Vijay Kedia, director Appointment of Mr. Vijay Kedia as Additional Director (Non-Executive Non Independent). Re-appointment of Mrs. Sujana Shah as an Independent Director for second term w.e.f. 7th May 2023. Reconciliation of Share Capital Audit report Grant of Options under ESOP Scheme 2021 (Oct 2022) Concall Invite Q2 FY 2023 Certificate ur. 74(5) – Q2 FY 2023 Allotment of Equity & Preference Shares by MMDL to Shalby Closure of Trading Window Q2 FY2023 Further Investment by MMDL in SGTPL (Aug 2022) Terms of Grant of Options Shalby Enters into Partnership with Australian Health Ed-Tech Company Concall Invite Q1 FY 2023 Reconciliation of Share Capital Audit Report Q1 FY 2023 Certificate ur. 74(5) – Q1 FY 2023 Grant of Options under ESOP Scheme 2021 (Jul 2022) Disclosure under SEBI (SAST) Regulations, 2011 (14 Jun 2022) SEBI (Prohibition of Insider Trading) Reg.2015 (14 Jun 2022) Grant of Options under ESOP Scheme 2021 (Jun 2022) Disclosure under SEBI (SAST) Regulations, 2011 (Jun 2022) SEBI (Prohibition of Insider Trading) Reg. 2015 (Jun 2022) Acq. of Shares by Shalby Employees Welfare Trust (May 2022) Grant of Options Under ESOP Scheme 2021 (May 2022)
Share Holder’s Meeting
Terms of appoitment of Independent Directors
Code of Conduct for Directors & Senior Management
Vigil Mechanism Whistleblower Policy
Nomination and Remuneration Policy
Risk Management Policy
Policy on Criteria for Determining Materiality of Events
Policy for Preservation of Documents
Performance Evaluation Policy for BOD
Material Subsidiary Policy
Director Familiarisation Policy
Familiarization Program Imparted to Independent Directors
Corporate Social Responsibility (CSR) Policy
Related Party Transaction Policy
Business Responsibility Report Policy
Dividend Distribution policy
Prevention of Insider Trading
Policy on Leak of UPSI
Shalby Limited ESOP Scheme 2021
- Dr. Vikram Shah – Chairman & Managing Director, Shalby Limited at Edelweiss India Conference (Feb’18):
- Dr. Vikram Shah – Chairman & Managing Director, Shalby Limited at IIFL Enterprising India IX-2018 (Feb’18):
- A Special Episode in CNBC Awaaz – Incredible Journey – Rising stars